SOLUBLE ICAM-A AS BIOMARKER FOR PREDICTION OF THERAPEUTIC RESPONSE Russian patent published in 2016 - IPC G01N33/574 G01N33/68 

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely to immunology, and may be used for analysing if a patient would provide a therapeutic response to a method of treating cancer; the method involves administering an immunogenic composition. That is ensured by taking a patient's blood sample and measuring sICAM-1 levels in the above blood sample. The low sICAM-1 levels less than approximately 300 ng/ml indicate that the patient is expected to develop a preventive or therapeutic response to the immunogenic composition. The immunogenic composition contains at least one recombinant vector expressing in vivo either the whole of one heterologous nucleotide sequence, or a part of it. What is also presented is a kit applicable for analysing if the patient would response to the administration of the immunogenic composition.

EFFECT: group of inventions provides selecting by low initial sICAM-1 values the patient suffering from cancer and expected to give an effective response to the therapy involving the administration of the immunogenic composition, particularly a vaccine.

19 cl, 2 dwg, 1 ex